Advancements in Systemic Therapy for Pancreatic Cancer
WEBMay 16, 2023 · New treatment strategies for advanced pancreatic cancer include switch maintenance with cytotoxic therapies, induction maintenance, and the utilization of targeted agents for patients with actionable variants, as well as ongoing development of cytotoxic regimens, such as NALIRIFOX.
Recent advances in immunotherapy for pancreatic cancer: a …
WEBA Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma [Internet]. clinicaltrials.gov; 2022 …
Survival Benefit of Pembrolizumab for Patients With Pancreatic ...
WEBMay 7, 2022 · Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with 5-year survival rate of 10%. Evidence about pembrolizumab usage for PDAC is limited even though it is Food and Drug Administration (FDA)-approved for treatment of advanced pancreatic cancer with deficient mismatch repair expression (dMMR) or high tumor mutational ...
Combination therapy for pancreatic cancer: anti-PD-(L)1-based …
WEBFeb 9, 2022 · This review, with a particular focus on pancreatic cancer therapy, collects current anti-PD-(L)1-based combination strategy, highlights potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving ...
Immunotherapy for pancreatic cancer - PMC - National Center for ...
WEBMay 6, 2021 · This review addresses the role of immune cells in the development of pancreatic cancer, the tumor microenvironment, the cancer immunity cycle, the mechanisms and efficacies of immunotherapeutic drugs in pancreatic cancer, and the response criteria for use in trials aimed at testing immunotherapeutics.
Systemic therapy in metastatic pancreatic adenocarcinoma: …
WEBJul 6, 2021 · The Food and Drug Administration (FDA) recently approved larotrectinib for patients with any tumors harboring a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, and pembrolizumab for patients with a mismatch repair deficiency in a second-line setting, including PDAC.
Exceptional Response to Olaparib and Pembrolizumab for Pancreatic …
WEBJan 27, 2022 · Five months after commencing maintenance pembrolizumab (10 months after his initial diagnosis), imaging revealed an excellent ongoing response with near-complete resolution of the pancreatic and liver tumors.
Personalized neoantigen vaccine and pembrolizumab in …
WEBApr 7, 2024 · Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance...
Motixafortide and Pembrolizumab Combined to Nanoliposomal …
WEBSep 15, 2021 · Purpose: Pancreatic ductal adenocarcinoma (PDAC) is largely unresponsive to checkpoint inhibitors. Blockade of the CXCR4/CXCL12 axis increases intratumoral trafficking of activated T cells while restraining immunosuppressive elements. This study evaluates dual blockade of CXCR4 and PD1 with chemotherapy in PDAC.
Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) …
WEBJun 2, 2022 · Abstract. 4158. Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death with a 5-year survival rate of 10%. Novel strategies for advanced PDAC are a critical need.
Skip to content